Scientech Research LLC Grows Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Scientech Research LLC grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 18.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,273 shares of the company’s stock after purchasing an additional 2,385 shares during the quarter. Scientech Research LLC’s holdings in Vaxcyte were worth $1,250,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PCVX. Nisa Investment Advisors LLC grew its position in shares of Vaxcyte by 21.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company’s stock valued at $220,000 after purchasing an additional 475 shares during the period. Avior Wealth Management LLC boosted its position in Vaxcyte by 21.1% during the fourth quarter. Avior Wealth Management LLC now owns 6,456 shares of the company’s stock worth $528,000 after acquiring an additional 1,124 shares during the last quarter. Blue Trust Inc. boosted its position in Vaxcyte by 125.1% during the fourth quarter. Blue Trust Inc. now owns 835 shares of the company’s stock worth $68,000 after acquiring an additional 464 shares during the last quarter. KBC Group NV boosted its position in Vaxcyte by 78.0% during the fourth quarter. KBC Group NV now owns 4,775 shares of the company’s stock worth $391,000 after acquiring an additional 2,092 shares during the last quarter. Finally, Chicago Partners Investment Group LLC boosted its position in Vaxcyte by 9.2% during the fourth quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company’s stock worth $440,000 after acquiring an additional 458 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PCVX shares. Guggenheim restated a “buy” rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Bank of America reduced their target price on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an “overweight” rating on the stock. Finally, The Goldman Sachs Group reduced their target price on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $136.50.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. This represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Stock Up 3.1%

PCVX opened at $31.85 on Friday. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06. The company has a 50 day moving average of $42.56 and a two-hundred day moving average of $71.95. The company has a market cap of $4.11 billion, a P/E ratio of -6.92 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the firm posted ($0.85) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.